Quarterly report pursuant to sections 13 or 15(d)

Consolidated Condensed Statements of Operations (Unaudited)

v2.4.0.6
Consolidated Condensed Statements of Operations (Unaudited) (USD $)
3 Months Ended
Mar. 31, 2012
Mar. 31, 2011
Consolidated Condensed Statements Of Operations    
Revenues $ 4,400 $ 0
Costs and expenses    
Research and development expenses 81,820 246,897
Loss on sale of research and development inventory 0 605,297
Plasma center operating expenses 461,493 376,698
General and administrative expenses 674,589 356,751
Total Costs and Expenses 1,217,902 1,585,643
Loss from Operations (1,213,502) (1,585,643)
Other income (expense)    
Interest income 7,067 640
Interest expense (8,494) (316,138)
Total Other Income (Expense) (1,427) (315,498)
Loss before income taxes (1,214,929) (1,901,141)
Income tax benefit 617,615 320,765
Net Loss $ (597,314) $ (1,580,376)
Net Loss per Share -    
Basic and Diluted $ (0.23) $ (4.5)
Weighted Average Number of Shares Outstanding - Basic and Diluted 2,648,087 351,535